US4321251A - Detection of malignant lesions of the oral cavity utilizing toluidine blue rinse - Google Patents
Detection of malignant lesions of the oral cavity utilizing toluidine blue rinse Download PDFInfo
- Publication number
- US4321251A US4321251A US06/105,079 US10507979A US4321251A US 4321251 A US4321251 A US 4321251A US 10507979 A US10507979 A US 10507979A US 4321251 A US4321251 A US 4321251A
- Authority
- US
- United States
- Prior art keywords
- rinse
- toluidine blue
- acetic acid
- water
- mouth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229950003937 tolonium Drugs 0.000 title claims abstract description 34
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 title claims abstract description 34
- 210000000214 mouth Anatomy 0.000 title claims abstract description 19
- 230000003902 lesion Effects 0.000 title claims abstract description 18
- 230000003211 malignant effect Effects 0.000 title claims abstract description 7
- 238000001514 detection method Methods 0.000 title description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 3
- 238000003759 clinical diagnosis Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 7
- 201000009030 Carcinoma Diseases 0.000 description 5
- 238000010827 pathological analysis Methods 0.000 description 4
- 208000009458 Carcinoma in Situ Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 201000004933 in situ carcinoma Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 238000004223 overdiagnosis Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003458 metachromatic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 208000020717 oral cavity carcinoma Diseases 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/42—Colour properties
Definitions
- the present invention involves the use of toluidine blue ##STR1## a basic metachromatic nuclear stain which stains nuclear material of malignant lesions but not normal mucosa, has been established as a useful modality for identifying malignant changes of the squamous mucosa. Its application is a simple, fast and inexpensive technique.
- One difficulty previously with the use of toluidine blue as a detecting agent has been some false negatives (underdiagnosis) as well as many false positives (overdiagnosis) and this difficulty has been found where toluidine blue was applied or applied in a neutral solution.
- a preferred method of clinical use is to utilize a rinse at Day 1 and if an area of stain is detected then select one day from Day 10 to Day 14 for an application to the detected area.
- toluidine rinse An advantageous use of the toluidine rinse was discovery of second primary cancers in the mouth or pharynx which were missed on clinical examination but were identified when the stain flowed into areas adjacent to or at a distance from the primary lesion. Application of stain indiscriminately to high risk areas resulted in the discovery of unobserved lesions.
- the present invention is devoted to the development of a toluidine blue mouth rinse which may be used as a routine procedure after thorough clinical examination to discover undetected lesions.
- a 1% toluidine blue solution containing acetic acid with alcohol was used. 1% by weight was selected as a preferred starting amount. Actually the toluidine blue may be utilized in as low amount as 0.5% and as high as 2%. A maximum pH of about 5 is achieved by the use of acetic acid which is preferred to mineral acids, such as hydrochloric or nitric.
- Table I compares pathological diagnosis with toluidine blue application results. Of 51 carcinomas, one stained negative for a false negative rate of 2.0%.
- Table II compares pathological diagnosis with toluidine blue Rinse A results. Of 51 carcinomas, 3 stained negative, for a false negative rate of 5.9%. Four of the 54 non-malignant lesions stained as positive for a false positive rate of 7.4%.
- Table III compares false negative and false positive rates using toluidine blue application and toluidine blue rinse.
- the rinse of the present invention has been shown to be effective in picking up lesions not observed. It is expected that, if a lesion is found with the rinse, a 10-14 day waiting period be allowed and then the specific area be re-stained by means of toluidine blue application. If it is positive once again, one must assume that the lesion is carcinoma (in-situ or invasive) unless proven otherwise. It may also be used in a situation where the rinse is utilized on Day 1 and again during the period Day 10 to Day 14.
- each rinse was ranked by extent and intensity of color. The ranks were then summed and averaged for each stain for a score that had the highest effectiveness. Rinse stain A ranked the highest and Rinse stains C and B ranked second and third, respectively.
- a stain is considered positive for malignancy if an area stained dark blue, either solid or stippled.
- a negative stain generally implied no absorption of the stain by a lesion, however, areas of light blue may occasionally appear after staining. This is usually related to mechanical surface retention or inadequate removal of a thin film of toluidine blue by the acetic acid and water rinse.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Optics & Photonics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
TABLE I ______________________________________ TOLUIDINE BLUE APPLICATION PATHOLOGICAL DX Positive Equivocal Negative Total ______________________________________ Carcinoma 37 -- 1 38 Carcinoma-in-Situ 12 1 -- 13 Atypia 1 1 1 3 Benign 3 -- 48 51 TOTAL 105 ______________________________________ False negatives = 1/51 = 2.0%. False positives = 5/54 = 9.3%* *If a pathological diagnosis of atypia is considered "premalignant", the false positive rate would be (3/51) 5.9%.
TABLE II ______________________________________ TOLUIDINE BLUE RINSE PATHOLOGICAL DX Positive Equivocal Negative Total ______________________________________ Carcinoma 34 2 2 38 Carcinoma-in-Situ 9 3 1 13 Atypia 2 -- 1 3 Benign 2 -- 49 51 TOTAL 105 ______________________________________ False Negatives = 3/51 - 5.9%. False positives = 4/54 = 7.4%* *If a pathological diagnosis of atypia is considered "premalignant", the false positive rate would be (2/51) 3.9%.
TABLE III ______________________________________ COMPARISON OF TOLUIDINE BLUE APPLICATION AND RINSE False Negatives False Positives ______________________________________ Toluidine Blue Application 2.0% 9.3% Toluidine Blue Rinse 5.9% 7.4% ______________________________________
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/105,079 US4321251A (en) | 1979-12-19 | 1979-12-19 | Detection of malignant lesions of the oral cavity utilizing toluidine blue rinse |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/105,079 US4321251A (en) | 1979-12-19 | 1979-12-19 | Detection of malignant lesions of the oral cavity utilizing toluidine blue rinse |
Publications (1)
Publication Number | Publication Date |
---|---|
US4321251A true US4321251A (en) | 1982-03-23 |
Family
ID=22303934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/105,079 Expired - Lifetime US4321251A (en) | 1979-12-19 | 1979-12-19 | Detection of malignant lesions of the oral cavity utilizing toluidine blue rinse |
Country Status (1)
Country | Link |
---|---|
US (1) | US4321251A (en) |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2655546A1 (en) * | 1989-12-11 | 1991-06-14 | Assistance Publique | COMPOSITION FOR INTRATUMORAL INJECTION, AND USE FOR PRECHEMOTHERAPIC AND PREOPERATIVE MARKING, IN LASEROTHERAPY AND THERMOTHERAPY. |
WO1993008847A1 (en) * | 1991-10-31 | 1993-05-13 | Ctm Associates, Inc. | Biological stain composition, method of preparation and method of use for delineation of epitheleal cancer |
WO1994016325A1 (en) * | 1993-01-14 | 1994-07-21 | Ctm Associates, Inc. | Method and kit for epithelial cancer screening |
EP0649667A2 (en) * | 1993-10-20 | 1995-04-26 | Antonella Aprile Carpenter | Quantum energy therapeutic biostimulation method and apparatus |
WO1995022279A1 (en) * | 1994-02-16 | 1995-08-24 | Zila Pharmaceuticals, Inc. | Videographic method for detecting cancer |
WO1997026018A1 (en) * | 1996-01-16 | 1997-07-24 | Zila Pharmaceuticals, Inc. | Methods and compositions for in-vivo detection of oral cancers and precancerous conditions |
WO1999025388A1 (en) * | 1997-11-13 | 1999-05-27 | Zila, Inc. | In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue |
US6086852A (en) * | 1997-11-13 | 2000-07-11 | Zila, Inc. | In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue |
AU725540B2 (en) * | 1993-01-14 | 2000-10-12 | Zila Biotechnology, Inc. | Method and kit for epithelial cancer screening |
US6152887A (en) * | 1998-02-27 | 2000-11-28 | Blume; Richard Stephen | Method and test kit for oral sampling and diagnosis |
WO2001054696A1 (en) * | 2000-01-31 | 2001-08-02 | Zila, Inc. | In vivo stain compounds and methods of use to identify dysplastic tissue |
WO2002007693A1 (en) * | 2000-07-20 | 2002-01-31 | Zila, Inc. | Improved diagnostic method for detecting dysplastic epithelial tissue |
WO2002026266A1 (en) * | 2000-09-26 | 2002-04-04 | Zila, Inc. | Method for early prediction of the onset of invasive cancer |
EP1212600A1 (en) * | 2000-06-30 | 2002-06-12 | Zila, Inc. | Methylene blue diagnostic agent and diagnostic methods for detection of epithelial cancer |
EP1214101A1 (en) * | 2000-02-28 | 2002-06-19 | Zila, Inc. | Method for detecting and killing epithelial cancer cells |
US6417003B1 (en) * | 1993-01-14 | 2002-07-09 | Zila, Inc. | Method and kit for epithelial cancer screening |
US20030017158A1 (en) * | 2002-03-08 | 2003-01-23 | Bernal Samuel D. | Method for detecting and killing epithelial cancer cells |
US20040146919A1 (en) * | 2002-05-18 | 2004-07-29 | Burkett Douglas D. | Method for early prediction of the onset of invasive cancer |
US20040158194A1 (en) * | 2003-02-06 | 2004-08-12 | Wolff Andy And Beiski Ben Z. | Oral devices and methods for controlled drug release |
EP1463838A1 (en) * | 2001-12-14 | 2004-10-06 | Zila Inc. | Stain-directed molecular analysis for cancer prognosis and diagnosis |
US20040247695A1 (en) * | 2001-08-28 | 2004-12-09 | Burkett Douglas D | Light-stabilized $I(in vivo) stain composition and method of manufacture |
US20050080343A1 (en) * | 2002-12-10 | 2005-04-14 | Board Of Regents, The University Of Texas System | Vision enhancement system for improved detection of epithelial neoplasia and other conditions |
US20060004110A1 (en) * | 2004-06-17 | 2006-01-05 | Sabnis Ram W | Composition and method for producing colored bubbles |
US20060110326A1 (en) * | 2002-06-04 | 2006-05-25 | Zila, Inc. | Toluidine blue o drug substance and use thereof for in vitro staining and chemotherapeutic treatment of dysplastic tissues |
US20060222675A1 (en) * | 2005-03-29 | 2006-10-05 | Sabnis Ram W | Personal care compositions with color changing indicator |
US20060222601A1 (en) * | 2005-03-29 | 2006-10-05 | Sabnis Ram W | Oral care compositions with color changing indicator |
US20060236470A1 (en) * | 2005-03-29 | 2006-10-26 | Sabnis Ram W | Novelty compositions with color changing indicator |
US20060257439A1 (en) * | 2005-03-29 | 2006-11-16 | Sabnis Ram W | Cleansing compositions with color changing indicator |
US20070010400A1 (en) * | 2005-07-06 | 2007-01-11 | Sabnis Ram W | Use of color changing indicators in consumer products |
US20070106138A1 (en) * | 2005-05-26 | 2007-05-10 | Beiski Ben Z | Intraoral apparatus for non-invasive blood and saliva monitoring & sensing |
US20080044351A1 (en) * | 2006-08-15 | 2008-02-21 | Xin Ye | Method and procedure to detect oral tissues with high-risk molecular profiles |
EP1944607A2 (en) | 1997-11-13 | 2008-07-16 | Zila, Inc. | Toluidine blue O compounds and their manufacture, analysis and use |
US20080299182A1 (en) * | 2007-03-01 | 2008-12-04 | Shuyuan Zhang | Methods and formulations for topical gene therapy |
US20090023138A1 (en) * | 2007-07-17 | 2009-01-22 | Zila Biotechnology, Inc. | Oral cancer markers and their detection |
US20100256125A1 (en) * | 2009-04-06 | 2010-10-07 | Zila Pharmaceuticals, Inc. | Use of improved toluidine blue in photodynamic therapy |
CN102221526A (en) * | 2011-03-09 | 2011-10-19 | 叶欣 | Composite reagent for screening early-stage oral intima cell disease and application method thereof |
US20190046665A1 (en) * | 2015-04-10 | 2019-02-14 | Memorial Sloan Kettering Cancer Center | Methods of cancer detection using parpi-fl |
CN110755642A (en) * | 2019-12-12 | 2020-02-07 | 华中农业大学 | A kind of compound dye and its application |
WO2021176449A1 (en) | 2020-03-03 | 2021-09-10 | Karmon Benny | Bone implant |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2628468A1 (en) * | 1975-06-27 | 1976-12-30 | Inst Nat Sante Rech Med | REAGENTS AND METHODS OF COUNTING BASOPHILS |
-
1979
- 1979-12-19 US US06/105,079 patent/US4321251A/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2628468A1 (en) * | 1975-06-27 | 1976-12-30 | Inst Nat Sante Rech Med | REAGENTS AND METHODS OF COUNTING BASOPHILS |
Non-Patent Citations (8)
Title |
---|
Benveniste, Chem. Abs., vol. 86, 1977, Ab. No. 86:102805j. * |
Mashberg, Cancer, Pub. pending. * |
Niebel, J. Amer. Dent. Assoc., vol. 68, 1964, pp. 801-806. * |
Ross, "Notes & Comments," Dental Abs., vol. 13, 1968, p. 453. * |
Shedd, Amer. J. Surg., vol. 110, 1965, pp. 631-634. * |
Shedd, Arch. Surg., vol. 95, 1967, pp. 16-22. * |
Strong, Arch. Otolaryng, vol. 87, May 1968, pp. 101-105. * |
Vaughan, Otolaryng, Clin. of NA, vol. 5, 1972, pp. 301-302. * |
Cited By (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991008776A1 (en) * | 1989-12-11 | 1991-06-27 | Assistance Publique | Composition for intratumoral injection and use for pre-chemotherapeutic and preoperative labelling in laser therapy and heat therapy |
FR2655546A1 (en) * | 1989-12-11 | 1991-06-14 | Assistance Publique | COMPOSITION FOR INTRATUMORAL INJECTION, AND USE FOR PRECHEMOTHERAPIC AND PREOPERATIVE MARKING, IN LASEROTHERAPY AND THERMOTHERAPY. |
WO1993008847A1 (en) * | 1991-10-31 | 1993-05-13 | Ctm Associates, Inc. | Biological stain composition, method of preparation and method of use for delineation of epitheleal cancer |
US5372801A (en) * | 1991-10-31 | 1994-12-13 | Ctm Associates, Inc. | Biological stain composition, method of preparation and method of use for delineation of epithelial cancer |
AU661727B2 (en) * | 1991-10-31 | 1995-08-03 | Zila Biotechnology, Inc. | Biological stain composition, method of preparation and method of use for delineation of epitheleal cancer |
AU696368B2 (en) * | 1993-01-14 | 1998-09-10 | Zila Biotechnology, Inc. | Method and kit for epithelial cancer screening |
WO1994016325A1 (en) * | 1993-01-14 | 1994-07-21 | Ctm Associates, Inc. | Method and kit for epithelial cancer screening |
AU725540B2 (en) * | 1993-01-14 | 2000-10-12 | Zila Biotechnology, Inc. | Method and kit for epithelial cancer screening |
US6417003B1 (en) * | 1993-01-14 | 2002-07-09 | Zila, Inc. | Method and kit for epithelial cancer screening |
EP0649667A3 (en) * | 1993-10-20 | 1995-05-17 | Antonella Aprile Carpenter | Quantum energy therapeutic biostimulation method and apparatus |
EP0649667A2 (en) * | 1993-10-20 | 1995-04-26 | Antonella Aprile Carpenter | Quantum energy therapeutic biostimulation method and apparatus |
WO1995022279A1 (en) * | 1994-02-16 | 1995-08-24 | Zila Pharmaceuticals, Inc. | Videographic method for detecting cancer |
WO1997026018A1 (en) * | 1996-01-16 | 1997-07-24 | Zila Pharmaceuticals, Inc. | Methods and compositions for in-vivo detection of oral cancers and precancerous conditions |
US5882627A (en) * | 1996-01-16 | 1999-03-16 | Zila Pharmaceuticals, Inc. | Methods and compositions for in-vivo detection of oral cancers precancerous conditions |
AU712732B2 (en) * | 1996-01-16 | 1999-11-11 | Zila Biotechnology, Inc. | Methods and compositions for in-vivo detection of oral cancers and precancerous conditions |
WO1999025388A1 (en) * | 1997-11-13 | 1999-05-27 | Zila, Inc. | In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue |
EP1944607A2 (en) | 1997-11-13 | 2008-07-16 | Zila, Inc. | Toluidine blue O compounds and their manufacture, analysis and use |
US6086852A (en) * | 1997-11-13 | 2000-07-11 | Zila, Inc. | In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue |
US6152887A (en) * | 1998-02-27 | 2000-11-28 | Blume; Richard Stephen | Method and test kit for oral sampling and diagnosis |
WO2001054696A1 (en) * | 2000-01-31 | 2001-08-02 | Zila, Inc. | In vivo stain compounds and methods of use to identify dysplastic tissue |
US6830743B1 (en) * | 2000-01-31 | 2004-12-14 | Zila Biotechnology, Inc. | In Vivo stain compounds and methods of use to identify dysplastic tissue |
EP1214101A1 (en) * | 2000-02-28 | 2002-06-19 | Zila, Inc. | Method for detecting and killing epithelial cancer cells |
EP1214101A4 (en) * | 2000-02-28 | 2005-04-13 | Zila Inc | Method for detecting and killing epithelial cancer cells |
EP1212600A1 (en) * | 2000-06-30 | 2002-06-12 | Zila, Inc. | Methylene blue diagnostic agent and diagnostic methods for detection of epithelial cancer |
EP1212600A4 (en) * | 2000-06-30 | 2007-10-10 | Zila Inc | Methylene blue diagnostic agent and diagnostic methods for detection of epithelial cancer |
AU785490B2 (en) * | 2000-07-20 | 2007-11-15 | Zila Biotechnology, Inc. | Improved diagnostic method for detecting dysplastic epithelial tissue |
WO2002007693A1 (en) * | 2000-07-20 | 2002-01-31 | Zila, Inc. | Improved diagnostic method for detecting dysplastic epithelial tissue |
EP1301164A4 (en) * | 2000-07-20 | 2005-10-05 | Zila Inc | Improved diagnostic method for detecting dysplastic epithelial tissue |
EP1301164A1 (en) * | 2000-07-20 | 2003-04-16 | Zila, Inc. | Improved diagnostic method for detecting dysplastic epithelial tissue |
US20040235067A1 (en) * | 2000-09-26 | 2004-11-25 | Burkett Douglas D | Stain-directed molecular analysis for cancer prognosis and diagnosis |
WO2002026266A1 (en) * | 2000-09-26 | 2002-04-04 | Zila, Inc. | Method for early prediction of the onset of invasive cancer |
US7659057B2 (en) * | 2000-09-26 | 2010-02-09 | Zila Biotechnology, Inc. | Stain-directed molecular analysis for cancer prognosis and diagnosis |
US20040247695A1 (en) * | 2001-08-28 | 2004-12-09 | Burkett Douglas D | Light-stabilized $I(in vivo) stain composition and method of manufacture |
US20090092552A1 (en) * | 2001-08-28 | 2009-04-09 | Zila Biotechnology, Inc. | Light stablized in vivo stain composition and method of manufacture |
US7462346B2 (en) * | 2001-08-28 | 2008-12-09 | Zila Biotechnology, Inc. | Light-stabilized(in vivo) stain composition and method of manufacture |
US7736625B2 (en) | 2001-08-28 | 2010-06-15 | Zila, Inc. | Light stabilized in vivo stain composition and method of manufacture |
EP1463833A1 (en) * | 2001-12-14 | 2004-10-06 | Zila Inc. | Light-directed molecular analysis for cancer prognosis and diagnosis |
EP1463838A1 (en) * | 2001-12-14 | 2004-10-06 | Zila Inc. | Stain-directed molecular analysis for cancer prognosis and diagnosis |
EP1463838A4 (en) * | 2001-12-14 | 2006-06-07 | Zila Inc | Stain-directed molecular analysis for cancer prognosis and diagnosis |
EP1463833A4 (en) * | 2001-12-14 | 2006-06-07 | Zila Inc | Light-directed molecular analysis for cancer prognosis and diagnosis |
US20030017158A1 (en) * | 2002-03-08 | 2003-01-23 | Bernal Samuel D. | Method for detecting and killing epithelial cancer cells |
US20040146919A1 (en) * | 2002-05-18 | 2004-07-29 | Burkett Douglas D. | Method for early prediction of the onset of invasive cancer |
US20060110326A1 (en) * | 2002-06-04 | 2006-05-25 | Zila, Inc. | Toluidine blue o drug substance and use thereof for in vitro staining and chemotherapeutic treatment of dysplastic tissues |
US7365844B2 (en) | 2002-12-10 | 2008-04-29 | Board Of Regents, The University Of Texas System | Vision enhancement system for improved detection of epithelial neoplasia and other conditions |
US20050080343A1 (en) * | 2002-12-10 | 2005-04-14 | Board Of Regents, The University Of Texas System | Vision enhancement system for improved detection of epithelial neoplasia and other conditions |
US20040158194A1 (en) * | 2003-02-06 | 2004-08-12 | Wolff Andy And Beiski Ben Z. | Oral devices and methods for controlled drug release |
US20060004110A1 (en) * | 2004-06-17 | 2006-01-05 | Sabnis Ram W | Composition and method for producing colored bubbles |
US7910531B2 (en) | 2004-06-17 | 2011-03-22 | C2C Technologies Llc | Composition and method for producing colored bubbles |
US20060222675A1 (en) * | 2005-03-29 | 2006-10-05 | Sabnis Ram W | Personal care compositions with color changing indicator |
US20060257439A1 (en) * | 2005-03-29 | 2006-11-16 | Sabnis Ram W | Cleansing compositions with color changing indicator |
US20060236470A1 (en) * | 2005-03-29 | 2006-10-26 | Sabnis Ram W | Novelty compositions with color changing indicator |
US20060222601A1 (en) * | 2005-03-29 | 2006-10-05 | Sabnis Ram W | Oral care compositions with color changing indicator |
US20070106138A1 (en) * | 2005-05-26 | 2007-05-10 | Beiski Ben Z | Intraoral apparatus for non-invasive blood and saliva monitoring & sensing |
US20070010400A1 (en) * | 2005-07-06 | 2007-01-11 | Sabnis Ram W | Use of color changing indicators in consumer products |
US20080044351A1 (en) * | 2006-08-15 | 2008-02-21 | Xin Ye | Method and procedure to detect oral tissues with high-risk molecular profiles |
US20080299182A1 (en) * | 2007-03-01 | 2008-12-04 | Shuyuan Zhang | Methods and formulations for topical gene therapy |
US20090023138A1 (en) * | 2007-07-17 | 2009-01-22 | Zila Biotechnology, Inc. | Oral cancer markers and their detection |
US20100256125A1 (en) * | 2009-04-06 | 2010-10-07 | Zila Pharmaceuticals, Inc. | Use of improved toluidine blue in photodynamic therapy |
CN102221526A (en) * | 2011-03-09 | 2011-10-19 | 叶欣 | Composite reagent for screening early-stage oral intima cell disease and application method thereof |
US20190046665A1 (en) * | 2015-04-10 | 2019-02-14 | Memorial Sloan Kettering Cancer Center | Methods of cancer detection using parpi-fl |
CN110755642A (en) * | 2019-12-12 | 2020-02-07 | 华中农业大学 | A kind of compound dye and its application |
WO2021176449A1 (en) | 2020-03-03 | 2021-09-10 | Karmon Benny | Bone implant |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4321251A (en) | Detection of malignant lesions of the oral cavity utilizing toluidine blue rinse | |
Mashberg | Tolonium (toluidine blue) rinse—a screening method for recognition of squamous carcinoma: Continuing study of oral cancer IV | |
Mashberg | Reevaluation of toluidine blue application as a diagnostic adjunct in the detection of asymptomatic oral squamous carcinoma: a continuing prospective study of oral cancer III | |
Kew et al. | Diagnosis of primary cancer of the liver | |
Bridge et al. | Primary adenocarcinoma of the jejunum and ileum. A clinicopathologic study | |
LIAW et al. | Alpha‐fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma | |
Bogomoletz et al. | Superficial squamous cell carcinoma of the esophagus: a report of 76 cases and review of the literature | |
Andersson et al. | Primary carcinoma of the appendix | |
Pandey et al. | Carcinoma of the Gallbladder | |
Rotman et al. | Adenocarcinoma of the duodenum: factors influencing survival | |
Fukui et al. | In vivo staining test with methylene blue for bladder cancer | |
Suzuki et al. | Endoscopic dyeing method for diagnosis of early cancer and intestinal metaplasia of the stomach | |
Little et al. | Chemical and physical properties of altered and sound enamel. 3. Fluoride and sodium content | |
Dombernowsky et al. | Peritoneoscopy in the staging of 190 patients with small‐cell anaplastic carcinoma of the lung with special reference to subtyping | |
Gierke et al. | Large-cell calcifying Sertoli cell tumor of the testis: appearance at sonography. | |
Chey et al. | Gastric secretion in patients with chronic pancreatitis and in chronic alcoholics | |
Ionescu et al. | Carcinoembryonic antigen and bladder carcinoma | |
Mulcahy et al. | Vaginal metastasis from renal cell carcinoma: radiographic evidence of possible route of spread | |
Wunderlich et al. | Effect of adjuvant chemo-or immunotherapy on the prognosis of colorectal cancer operated for cure | |
CA1180648A (en) | Toluidine blue rinse for the detection of squamous carcinoma of the oral cavity | |
Cabré‐Fiol et al. | Progress in the cytological diagnosis of gastric lymphoma. A report of 32 cases | |
Lieskovsky et al. | Significance of serum lactic dehydrogenase in stages B and C non-seminomatous testis tumors | |
Kuwano et al. | Determination of the resection line in early esophageal cancer using intraoperative endoscopic examination with Lugol staining | |
Giler et al. | Peroral staining method with toluidine blue as an aid in the diagnosis of malignant gastric lesions. | |
Prioleau Jr et al. | Dirofilaria immitis (dog heartworm) as a pulmonary lesion in humans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNITED STATES OF AMERICA, AS REPRESENTED BY THE SE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:MASHBERG ARTHUR;REEL/FRAME:003885/0825 Effective date: 19791226 Owner name: UNITED STATES OF AMERICA, AS REPRESENTED BY THE SE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MASHBERG ARTHUR;REEL/FRAME:003885/0825 Effective date: 19791226 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
RF | Reissue application filed |
Effective date: 19830302 |
|
AS | Assignment |
Owner name: ZILA, INC., ARIZONA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CTM ASSOCIATES, INC., A PENNSYLVANIA CORPORATION;REEL/FRAME:007863/0859 Effective date: 19911231 Owner name: CTM ASSOCIATES, A CORPORATION, PENNSYLVANIA Free format text: EXCLUSIVE LICENSE;ASSIGNOR:COMMERCE, DEPARTMENT OF, UNITED STATES OF AMERICA, THE;REEL/FRAME:007803/0866 Effective date: 19920930 |
|
PTEF | Application for a patent term extension |
Free format text: PRODUCT NAME: ORATEST Filing date: 19990301 Expiry date: 19990323 |
|
AS | Assignment |
Owner name: CONGRESS FINANCIAL CORPORATION (WESTERN), CALIFORN Free format text: SECURITY INTEREST;ASSIGNOR:ZILA, INC.;REEL/FRAME:012134/0895 Effective date: 20010817 |
|
AS | Assignment |
Owner name: BLACK DIAMOND COMMERCIAL FINANCE, L.L.C.,CONNECTIC Free format text: SECURITY AGREEMENT;ASSIGNORS:ZILA, INC.;ZILA BIOTECHNOLOGY, INC.;ZILA NUTRACEUTICALS, INC.;AND OTHERS;REEL/FRAME:017411/0081 Effective date: 20060324 Owner name: BLACK DIAMOND COMMERCIAL FINANCE, L.L.C., CONNECTI Free format text: SECURITY AGREEMENT;ASSIGNORS:ZILA, INC.;ZILA BIOTECHNOLOGY, INC.;ZILA NUTRACEUTICALS, INC.;AND OTHERS;REEL/FRAME:017411/0081 Effective date: 20060324 |
|
AS | Assignment |
Owner name: ZILA, INC., ARIZONA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CONGRESS FINANCIAL CORPORATION (WESTERN);REEL/FRAME:017931/0198 Effective date: 20060713 |
|
AS | Assignment |
Owner name: ZILA, INC., ARIZONA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BLACK DIAMOND COMMERCIAL FINANCE, L.L.C.;REEL/FRAME:018323/0754 Effective date: 20061002 Owner name: ZILA BIOTECHNOLOGY, INC., ARIZONA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BLACK DIAMOND COMMERCIAL FINANCE, L.L.C.;REEL/FRAME:018323/0754 Effective date: 20061002 Owner name: ZILA, INC.,ARIZONA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BLACK DIAMOND COMMERCIAL FINANCE, L.L.C.;REEL/FRAME:018323/0754 Effective date: 20061002 Owner name: ZILA BIOTECHNOLOGY, INC.,ARIZONA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BLACK DIAMOND COMMERCIAL FINANCE, L.L.C.;REEL/FRAME:018323/0754 Effective date: 20061002 Owner name: ZILA TECHNICAL, INC.,ARIZONA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BLACK DIAMOND COMMERCIAL FINANCE, L.L.C.;REEL/FRAME:018323/0754 Effective date: 20061002 Owner name: ZILA NUTRACEUTICALS, INC.,ARIZONA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BLACK DIAMOND COMMERCIAL FINANCE, L.L.C.;REEL/FRAME:018323/0754 Effective date: 20061002 Owner name: ZILA SWAB TECHNOLOGIES, INC.,ARIZONA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BLACK DIAMOND COMMERCIAL FINANCE, L.L.C.;REEL/FRAME:018323/0754 Effective date: 20061002 Owner name: ZILA TECHNICAL, INC., ARIZONA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BLACK DIAMOND COMMERCIAL FINANCE, L.L.C.;REEL/FRAME:018323/0754 Effective date: 20061002 Owner name: ZILA NUTRACEUTICALS, INC., ARIZONA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BLACK DIAMOND COMMERCIAL FINANCE, L.L.C.;REEL/FRAME:018323/0754 Effective date: 20061002 Owner name: ZILA SWAB TECHNOLOGIES, INC., ARIZONA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BLACK DIAMOND COMMERCIAL FINANCE, L.L.C.;REEL/FRAME:018323/0754 Effective date: 20061002 |